Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

OBJECTIVE: Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gui, Lin, Cao, Junning, Ji, Dongmei, Zhang, Huilai, Fan, Qian, Zhu, Jun, Song, Yuqin, Jiang, Shiyu, Ning, Zhiqiang, Yu, Jia, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580795/
https://www.ncbi.nlm.nih.gov/pubmed/34815635
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.05.08

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580795/
https://www.ncbi.nlm.nih.gov/pubmed/34815635
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.05.08

Ejemplares similares